Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection

Recent recombinant DNA technology has provided novel approaches to develop marker and safe vaccines against bluetongue virus (BTV). To develop new vaccination strategies against BTV infection we have engineered naked DNAs and recombinant modified vaccinia virus Ankara (rMVA) expressing VP2, VP5 and VP7 proteins from BTV-4. IFNAR(-/-) mice inoculated with DNA/rMVA-VP2, -VP5, -VP7 in an heterologous prime boost vaccination strategy generated significant levels of neutralizing antibodies against BTV-4 and they were completely protected against BTV-4 challenge. Interestingly, VP2 and VP7 proteins expressed in the DNA/rMVA vaccines induced a specific BTV T-cell response that might contribute to the protection of IFNAR(-/-) mice against challenge with BTV-4. In addition, antibodies against VP2, VP5, and VP7, but not NS3 were detected in the sera of DNA/rMVA-VP2, -VP5, -VP7 immunized mice confirming the DIVA (differentiating infected from vaccinated animals) properties of this vaccine. Overall, our results show that the heterologous prime boost vaccination with DNA/rMVA expressing VP2, VP5, and VP7 proteins protects against BTV-4 infection. © 2009 Elsevier Ltd. All rights reserved.